Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 2Meningioma 2von Hippel-Lindau Disease 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Metastatic Neuroendocrine Prostate Cancer 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Ganglioneuroma 1Ganglioneuroblastoma 1Carcinoma, Neuroendocrine 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 39Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Standard of Care 17Nivolumab 17Carboplatin 17Paclitaxel 15Exercise 15Gemcitabine 14atezolizumab 13Pemetrexed 13Cisplatin 13Radiotherapy 11Fluorouracil 11Doxorubicin 11Cetuximab 10130-nm albumin-bound paclitaxel 10durvalumab 9Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9Biopsy 9abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Prednisone 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × gallium Ga 68 dotatate × 90 days × Clear all
NCT07284589 2026-04-08

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Nuclear Imaging Institute

Phase 2 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡